MENU
+Compare
HRTS
ETF ticker: NASDAQ
AS OF
Oct 17 closing price
Price
$32.26
Change
+$0.10 (+0.31%)
Net Assets
50.65M

HRTS stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for HRTS with price predictions
Oct 16, 2025

HRTS saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for HRTS moved out of overbought territory on October 16, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 26 similar instances where the indicator exited the overbought zone. In of the 26 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HRTS moved out of overbought territory on October 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 11 similar instances where the indicator moved out of overbought territory. In of the 11 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for HRTS turned negative on October 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 22 similar instances when the indicator turned negative. In of the 22 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HRTS broke above its upper Bollinger Band on September 30, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 29, 2025. You may want to consider a long position or call options on HRTS as a result. In of 27 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTS advanced for three days, in of 120 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 59 cases where HRTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Unitedhealth Group (NYSE:UNH), AstraZeneca PLC (NASDAQ:AZN), Abbott Laboratories (NYSE:ABT), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Boston Scientific Corp (NYSE:BSX), Medtronic plc (NYSE:MDT).

Industry description

The investment seeks to provide long-term growth of capital. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Heart & Health ETF ETF is 91.42B. The market cap for tickers in the group ranges from 3.51M to 719.7B. LLY holds the highest valuation in this group at 719.7B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Heart & Health ETF ETF was 30%. For the same ETF, the average monthly price growth was 99%, and the average quarterly price growth was 304%. RCKT experienced the highest price growth at 9%, while GPCR experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Tema Heart & Health ETF ETF was -24%. For the same stocks of the ETF, the average monthly volume growth was -11% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 70
Price Growth Rating: 72
SMR Rating: 100
Profit Risk Rating: 66
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co